Katie Ellias
Managing Director @ JDRF T1D Fund
Paris, France
Katie Ellias is a seed investor at JDRF T1D Fund in Paris focused on Biotechnology and Medical. Katie Ellias is the managing director of the JDRF T1D Fund. She attended the Wharton School and Yale University.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Katie Ellias invests in
Stages Katie Ellias invests in
Countries Katie Ellias invests in
Investment Focus
Industry
- Biotechnology 7 (70%)
- Medical 3 (30%)
- Health Care 3 (30%)
- Therapeutics 3 (30%)
- Life Science 2 (20%)
Stage
- Seed 3 (30%)
- Series A 3 (30%)
- Venture - Series Unknown 2 (20%)
- Series B 1 (10%)
- Funding Round 1 (10%)
Country
- United States 6 (60%)
- France 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Veralox Therapeutics
|
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. | $24M / Jun 20, 2023 | |
Jaguar Gene Therapy
|
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. | Venture - Series Unknown / Mar 29, 2022 | |
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series B / Nov 02, 2021 | |
|
Veralox Therapeutics
|
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. | $16.6M / Series A / Jun 16, 2021 | |
DiogenX
|
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patientswith diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes. | $5.1M / Seed / Jun 16, 2020 | |
i2o Therapeutics
|
i2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, it leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2o isfocused on creating the next generation of oral peptide and protein-based therapies.The company was founded in 2019 and based in Saratoga, California. | $4M / Seed / Apr 09, 2020 | |
Repertoire Immune Medicines
|
Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15. | Venture - Series Unknown / Mar 25, 2020 | |
IMTherapeutics
|
IM Therapeutics develops personalized immunotherapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Their lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Their goal is to preserve pancreaticbeta-cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. They are leveraging Their HLA platform to expand their pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases.It was founded in 2015 and is headquartered in Aurora, Colorado. | $10M / Series A / Oct 09, 2019 | |
|
Veralox Therapeutics
|
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients. | $5.4M / Seed / Sep 05, 2019 | |
|
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $4.8M / Series A / Mar 28, 2019 |
Co-Investors
About JDRF T1D Fund
The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.
JDRF T1D Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brian Malik
Investment Professional
|
|||
Jerry Wisler
Member, Investment Committee
|
|||
Jonathan Behr
Managing Director
|
|||
Jonathan Behr
Managing Director
|
|||
|
Katie Ellias
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Katie Ellias invest in?
Katie Ellias invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series A stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Katie Ellias last invest?
The most recent investment recorded for Katie Ellias closed in Jun 2023. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
